Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer. Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction. An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider permanent discontinuation of Nexavar. continue reading below »
HCC is usually a slow-growing tumor with long latency, diagnosed at an advanced stage due to its asymptomatic nature in the early stages. Five-year relative survival rate is 14%, depending on the stage of diagnosis.1 Previously, treatment options were limited to surgical resection, liver transplantation, local ablation, percutaneous ablation, and transarterial embolization/chemoembolization.2
Nexavar provides another treatment option in HCC, enabling you to develop a therapeutic plan that helps meet your patients' needs. As the first and only oral systemic treatment to significantly improve overall survival in patients with unresectable HCC, Nexavar may help you offer your patients an option that may extend survival.3
HCC is a complex disease that may require a dynamic treatment approach
The patient is central to all treatment considerations
MAKE SURE YOUR TEAM EVALUATES NEXAVAR FOR INCORPORATION INTO THE TREATMENT PLAN FOR UNRESECTABLE HCCRead more about:
References: 1. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society; 2012. 2. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25(27):3866-3884. 3. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.